Effect of a Chikungunya Virus–Like Particle Vaccine on Safety and Tolerability Outcomes

Grace Chen(Johns Hopkins University), Bruno Hoen(Inserm), Nina M. Berkowitz(National Institutes of Health), Charla Andrews(National Institutes of Health), Richard A. Koup(Aaron Diamond AIDS Research Center), Jean W. Pape(Gheskio Centers), Barney S. Graham(National Institutes of Health), Nicolas Rosario(San Juan City Hospital), Brittanie Brockett(National Institutes of Health), Kevin Carlton(National Institute of Allergy and Infectious Diseases), Jason Mendy(Emergent BioSolutions (United States)), Emily E. Coates(National Institutes of Health), Brenda Larkin(National Institutes of Health), Theodore C. Pierson(National Institutes of Health), Florence Kaltovich(National Institutes of Health), André Cabie, Doug Haney(Emergent BioSolutions (United States)), Ingelise J. Gordon(National Institute of Allergy and Infectious Diseases), Kimberly A. Dowd(Johns Hopkins University), Robert T. Bailer(National Institutes of Health), John R. Mascola(National Institute of Allergy and Infectious Diseases), Amy Bray(Emmes (United States)), Jason G. Gall(GenVec), Mark O’Callahan(National Institutes of Health), Julie E. Ledgerwood(Vaccine Research Institute of San Diego), Cristina A. Carter(National Institutes of Health), Josephine H. Cox(International AIDS Vaccine Initiative), Yeycy Donastorg, Allison Beck, Richard Schwartz(National Institutes of Health), David Gordon(Universidade Federal de Ouro Preto), Clemente Díaz(University of Puerto Rico System), Michelle Conan-Cibotti(National Institutes of Health), Jeanine May(Emmes (United States)), Rebecca Lampley(National Institutes of Health), Sarah H. Plummer(National Institutes of Health)
JAMA
April 14, 2020
Cited by 109


Related Papers